SHR 9549
Alternative Names: SHR-9549Latest Information Update: 19 Sep 2022
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Small molecules
- Mechanism of Action Estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 19 Sep 2022 Discontinued - Phase-I for Breast cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (Jiangsu Hengrui Medicine pipeline, September 2022)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Breast-cancer in China (PO, Tablet)
- 14 Oct 2019 Jiangsu Hengrui Medicine terminates a phase I trial in Breast cancer (Late-stage disease, Second-line therapy or greater) in China (PO) due to sponsor's R & D Strategy Adjustment (NCT03596658)